Elixiron Immunotherapeutics (Cayman) Limited
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Precision Immunotherapy
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
Develops therapies that precisely modulate disease-specific immune imbalances by targeting key pathways and biomarkers to address root causes.
2. mRNA Therapeutics Platform
Uses mRNA to direct in-vivo production of therapeutic proteins, enabling highly targeted treatments across applications from cancer immunotherapy to gene editing, while reducing development time and cost
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60600720
Status
Active
Number of Employees
0
Total Paid-in
Capital
- (NT$)
Exit Status
Emerging Stock Exchange(2026)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Elixiron Immunotherapeutics focuses on developing precision immunotherapies targeting neuroinflammation, autoimmune diseases, and cancer. Leveraging deep expertise in immunology and drug development, the company has advanced two high-potential lead candidates into clinical trials: EI-1071 (Enrupatinib), for Alzheimer’s disease, ALS, Parkinson’s disease, and idiopathic pulmonary fibrosis, and EI-001 (Indemakitug), for vitiligo, hemophagocytic syndrome, and alopecia areata.
The content above was translated by Ai
